Tessera Therapeutics
Tessera Therapeutics develops a genome-engineering platform that programs durable genomic alterations using RNA- and DNA-based 'gene writing' approaches. The company combines discovery of mobile genetic element mechanisms, computational candidate screening, engineered gene-writing machineries, and tissue-targeted non-viral lipid nanoparticle delivery to advance preclinical therapeutic programs across liver, hematopoietic stem cells, T cells and lung.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Genome engineering platform (RNA and DNA gene writing)
A platform composed of modular RNA- and DNA-based gene-writing systems designed to enable precise and durable genomic alterations for therapeutic purposes.
Gene Writing
Proprietary technology and LNP delivery system designed to alter the human genome and effect precise, durable therapeutic change.
Genome engineering platform (RNA and DNA gene writing)
A platform composed of modular RNA- and DNA-based gene-writing systems designed to enable precise and durable genomic alterations for therapeutic purposes.
Gene Writing
Proprietary technology and LNP delivery system designed to alter the human genome and effect precise, durable therapeutic change.
Services
Development and optimization of tissue-targeted LNP delivery systems for RNA therapeutics to support in vivo and ex vivo applications.
Development and optimization of tissue-targeted LNP delivery systems for RNA therapeutics to support in vivo and ex vivo applications.
Expertise Areas
- Genome engineering using gene-writing approaches
- RNA therapeutics and mRNA platform development
- Non-viral lipid nanoparticle delivery and targeting
- Discovery and engineering of mobile genetic elements
Key Technologies
- Target-primed reverse transcription (TPRT)
- RNA-based gene writers (mRNA + template RNA)
- DNA-based integration without double-stranded breaks
- Lipid nanoparticle (LNP) formulation and targeting
News & Updates
Press release announcing presentation of new preclinical in vivo data for sickle cell disease and T cell therapy programs.
Press release announcing award funding from ARPA-H to support in vivo CAR-T therapy development.
Press release summarizing new preclinical results across in vivo gene writing programs and advancements in the delivery platform.
Press release announcing presentation of new preclinical in vivo data for sickle cell disease and T cell therapy programs.
Press release announcing award funding from ARPA-H to support in vivo CAR-T therapy development.
Press release summarizing new preclinical results across in vivo gene writing programs and advancements in the delivery platform.